Skip to main
ATXS
ATXS logo

Astria Therapeutics (ATXS) Stock Forecast & Price Target

Astria Therapeutics (ATXS) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

The positive outlook on Astria Therapeutics's stock is supported by the anticipated momentum in 2025, driven by clinical updates and promising data from its key programs, STAR-0215 and STAR-0310, which address significant medical needs in hereditary angioedema (HAE) and atopic dermatitis. The impressive results from the ALPHA-STAR Phase 1b/2 clinical trial, which demonstrated a 90-95% reduction in monthly attack rates for HAE patients, along with favorable pharmacokinetics and pharmacodynamics, bolster confidence in the therapeutic potential of navenibart as a differentiated prophylactic treatment. Additionally, the preclinical data for STAR-0310 reveal a substantial enhancement in binding affinity and reduced cytotoxicity compared to existing therapies, indicating a strong advantage that may translate into effective treatment options for patients with atopic dermatitis.

Bears say

Astria Therapeutics faces significant risks that contribute to a negative outlook on its stock, primarily stemming from the potential for failed clinical trials and inadequate funding, which could hinder the progression of its drug candidates. The company reported fourth-quarter and full-year financial results that indicate higher-than-expected losses, with earnings per share (EPS) at ($0.44) for 4Q24 and ($1.68) for the full year, slightly better but still below estimates. Additionally, the competitive landscape poses challenges, particularly in achieving commercial success against established products like Dupixent, highlighting an uncertain efficacy/safety profile that could further impact investor confidence and stock performance.

Astria Therapeutics (ATXS) has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Astria Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Astria Therapeutics (ATXS) Forecast

Analysts have given Astria Therapeutics (ATXS) a Buy based on their latest research and market trends.

According to 9 analysts, Astria Therapeutics (ATXS) has a Buy consensus rating as of Aug 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Astria Therapeutics (ATXS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.